GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (NAS:SYNH) » Definitions » Sloan Ratio %

Syneos Health (Syneos Health) Sloan Ratio % : -1.00% (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Syneos Health Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Syneos Health's Sloan Ratio for the quarter that ended in Jun. 2023 was -1.00%.

As of Jun. 2023, Syneos Health has a Sloan Ratio of -1.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Syneos Health Sloan Ratio % Historical Data

The historical data trend for Syneos Health's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Sloan Ratio % Chart

Syneos Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.84 -1.42 3.37 1.52 -0.67

Syneos Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.84 -0.52 -0.67 -1.61 -1.00

Competitive Comparison of Syneos Health's Sloan Ratio %

For the Diagnostics & Research subindustry, Syneos Health's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syneos Health's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Syneos Health's Sloan Ratio % falls into.



Syneos Health Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Syneos Health's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(266.497-426.981
--105.634)/8199.218
=-0.67%

Syneos Health's Sloan Ratio for the quarter that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2023 )
=(71.221-252.934
--101.098)/8075.381
=-1.00%

Syneos Health's Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was 87.049 (Sep. 2022 ) + 55.528 (Dec. 2022 ) + -72.149 (Mar. 2023 ) + 0.793 (Jun. 2023 ) = $71 Mil.
Syneos Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was 132.375 (Sep. 2022 ) + 123.817 (Dec. 2022 ) + 30.424 (Mar. 2023 ) + -33.682 (Jun. 2023 ) = $253 Mil.
Syneos Health's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 was -28.484 (Sep. 2022 ) + -26.087 (Dec. 2022 ) + -27.622 (Mar. 2023 ) + -18.905 (Jun. 2023 ) = $-101 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syneos Health  (NAS:SYNH) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2023, Syneos Health has a Sloan Ratio of -1.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Syneos Health Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Syneos Health's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syneos Health (Syneos Health) Business Description

Traded in Other Exchanges
N/A
Address
1030 Sync Street, Morrisville, NC, USA, 27560-5468
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
Executives
Michael J. Bonello officer: Chief Financial Officer 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Stanford Rudnick officer: See remarks C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Christian Tucat officer: Chief Business Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Michael Lee Brooks officer: See remarks C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jonathan Olefson officer: General Counsel & Corp Secty C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Michelle Keefe officer: Pres., Commercial Solutions C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jason M. Meggs officer: Chief Financial Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Donna Hildebrand Kralowetz officer: SVP, Chief Accounting Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Matthew E. Monaghan director ONE INVACARE WAY, ELYRIA OH 44035
Alfonso G Zulueta director 4925 INDIANA AVE, LISLE IL 60532
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Linda S Harty director MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432
Alistair Macdonald officer: Chief Operating Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
David S. Wilkes director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Advent International Corp/ma 10 percent owner 800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199

Syneos Health (Syneos Health) Headlines

From GuruFocus